OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder

OMass Therapeutics raises $310M for genetic adrenal disorder treatment

UK biotech OMass Therapeutics collected $310 million in one of the largest private financings for a British biotech in recent years, seeking to develop treatments for congenital adrenal hyperplasia and compete with Neurocrine and Vertex.